|
|
Volumn , Issue 59, 2007, Pages 185-193
|
|
The role of PET scanning in determining pharmacoselective doses in oncology drug development.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
FLUORODEOXYGLUCOSE F 18;
ANIMAL;
BRAIN TUMOR;
CHEMICAL MODEL;
DOSE RESPONSE;
DRUG DESIGN;
HUMAN;
METABOLISM;
METHODOLOGY;
NEOPLASM;
PATHOLOGY;
PERFUSION;
PHARMACEUTICS;
POSITRON EMISSION TOMOGRAPHY;
REVIEW;
TIME;
ANIMALS;
ANTINEOPLASTIC AGENTS;
BRAIN NEOPLASMS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG DESIGN;
FLUORODEOXYGLUCOSE F18;
HUMANS;
MODELS, CHEMICAL;
NEOPLASMS;
PERFUSION;
POSITRON-EMISSION TOMOGRAPHY;
TECHNOLOGY, PHARMACEUTICAL;
TIME FACTORS;
MLCS;
MLOWN;
|
|
EID: 39049183365
PISSN: 09476075
EISSN: None
Source Type: Journal
DOI: 10.1007/978-3-540-49529-1_14 Document Type: Review |
|
Times cited : (4)
|
|
References (12)
|
